In 2018, after President Donald Trump publicly condemned the pharmaceutical industry for skyrocketing prescription drug prices, several of the largest drug manufacturers — including Merck, Novartis, Pfizer and Roche — announced a series of temporary price freezes to their brand-name medications.
While touted as a victory by the Trump administration, industry experts were quick to note that without new drug-pricing policies, drug manufacturers were likely to compensate for the losses with significant increases in 2019 — which is exactly what happened, according to a report
Uncategorized